To date, the only available treatments, such as lipid-lowing agents, immune regulators, antiviral and anti-cancer agents, microRNAs, and combined therapies (e.g., IL-2 and IFN), regulate NK cell activation to inhibit fibrosis-causing factors. This evidence concerns the gene IL2 and cancer.